Corebridge Financial Inc. Buys 203,500 Shares of Hims & Hers Health, Inc. $HIMS

Key Points

• Corebridge Financial Inc. significantly increased its holdings in Hims & Hers Health by 201.3%, owning approximately 304,591 shares worth $9,001,000 at the end of the last reporting period.
• Despite a revenue increase of 72.6% year-over-year, Hims & Hers Health reported earnings of $0.17 per share, which was below analysts' expectations of $0.18.
• The stock currently stands at around $44.07, with a market capitalization of $9.96 billion and a PE ratio of 55.09.

Corebridge Financial Inc. grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 201.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 304,591 shares of the company's stock after buying an additional 203,500 shares during the quarter. Corebridge Financial Inc. owned 0.14% of Hims & Hers Health worth $9,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Freedom Investment Management Inc. bought a new position in shares of Hims & Hers Health during the 1st quarter valued at $380,000. MetLife Investment Management LLC raised its holdings in Hims & Hers Health by 87.9% in the 1st quarter. MetLife Investment Management LLC now owns 215,753 shares of the company's stock worth $6,376,000 after purchasing an additional 100,957 shares during the period. Napa Wealth Management bought a new position in Hims & Hers Health in the 1st quarter worth $201,000. Jump Financial LLC increased its position in Hims & Hers Health by 633.2% in the first quarter. Jump Financial LLC now owns 725,445 shares of the company's stock worth $21,437,000 after buying an additional 626,496 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after buying an additional 227 shares during the period. 63.52% of the stock is owned by institutional investors.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,571 shares of Hims & Hers Health stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.53, for a total value of $114,486.63. Following the sale, the insider directly owned 150,450 shares of the company's stock, valued at approximately $6,699,538.50. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $43.69, for a total value of $505,973.89. Following the completion of the sale, the chief financial officer directly owned 116,806 shares in the company, valued at $5,103,254.14. This trade represents a 9.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,395,428 shares of company stock valued at $71,753,898. 13.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $1.76 on Friday, reaching $42.36. 16,080,388 shares of the company's stock traded hands, compared to its average volume of 29,952,310. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock has a 50-day simple moving average of $49.98 and a 200-day simple moving average of $45.82. The firm has a market cap of $9.57 billion, a PE ratio of 52.95, a P/E/G ratio of 2.98 and a beta of 2.08. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue was up 72.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HIMS. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.